Senapati et al.reported in a prospective study that decitabine maintenance in CBF-AML patients in CR1 after intensive chemotherapy with persistent molecular disease led to complete molecular response in 52% of cases (n = 12/23) [54]. Here, CEBPZ is linked to acute myeloid leukemia.